D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin… - Proceedings of the …, 2022 - National Acad Sciences
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin… - Proceedings of the …, 2022 - pubmed.ncbi.nlm.nih.gov
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin, J He… - Proceedings of the …, 2022 - ui.adsabs.harvard.edu
PD-L1 is well known as an immune checkpoint molecule, which suppresses immune
surveillance through binding to its receptor PD-1. Intracellular PD-L1 can also protect …
surveillance through binding to its receptor PD-1. Intracellular PD-L1 can also protect …
[HTML][HTML] D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin, J He… - Proceedings of the …, 2022 - ncbi.nlm.nih.gov
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
[PDF][PDF] D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhanga, Y Yanga, W Donga, M Lina, J Hea… - PNAS, 2022 - researchgate.net
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1
R Zhang, Y Yang, W Dong, M Lin, J He… - Proceedings of the …, 2022 - cir.nii.ac.jp
抄録< jats: title> Significance</jats: title>< jats: p> PD-L1 is well known as an immune
checkpoint molecule, which suppresses immune surveillance through binding to its receptor …
checkpoint molecule, which suppresses immune surveillance through binding to its receptor …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
R Zhang, Y Yang, W Dong, M Lin, J He… - Proceedings of the …, 2022 - europepmc.org
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
R Zhang, Y Yang, W Dong, M Lin, J He… - Proceedings of the …, 2022 - europepmc.org
Breast cancer is the most frequent malignancy in women worldwide, and triple-negative
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …
breast cancer (TNBC) patients have the worst prognosis and highest risk of recurrence. The …